Pyxis Oncology (NASDAQ:PYXS) Price Target Raised to $10.00

Pyxis Oncology (NASDAQ:PYXS) had its price target lifted by Royal Bank of Canada from $7.00 to $10.00 in a research report sent to investors on Thursday,Benzinga reports. They currently have an outperform rating on the stock.

PYXS has been the subject of a number of other research reports. William Blair cut shares of Pyxis Oncology from an “outperform” rating to a “market perform” rating in a research report on Thursday. Stephens assumed coverage on shares of Pyxis Oncology in a research report on Friday, November 8th. They set an “overweight” rating and a $13.00 target price for the company. Stifel Nicolaus assumed coverage on shares of Pyxis Oncology in a research report on Thursday, August 8th. They issued a “buy” rating and a $10.00 price objective for the company. Finally, HC Wainwright reissued a “buy” rating and issued a $7.00 price objective on shares of Pyxis Oncology in a research report on Thursday. One research analyst has rated the stock with a hold rating and eight have given a buy rating to the company. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $10.00.

Pyxis Oncology Trading Down 9.5 %

Shares of PYXS opened at $1.90 on Thursday. The stock has a market cap of $112.99 million, a P/E ratio of -1.84 and a beta of 1.27. The company has a 50-day moving average of $3.64 and a two-hundred day moving average of $3.61. Pyxis Oncology has a 12-month low of $1.35 and a 12-month high of $6.85.

Hedge Funds Weigh In On Pyxis Oncology

Several institutional investors and hedge funds have recently bought and sold shares of PYXS. Fullcircle Wealth LLC acquired a new position in Pyxis Oncology during the second quarter worth approximately $40,000. Intech Investment Management LLC acquired a new position in Pyxis Oncology during the third quarter worth approximately $55,000. SG Americas Securities LLC acquired a new position in Pyxis Oncology during the third quarter worth approximately $58,000. The Manufacturers Life Insurance Company acquired a new position in Pyxis Oncology during the second quarter worth approximately $65,000. Finally, MetLife Investment Management LLC increased its position in Pyxis Oncology by 41.1% during the third quarter. MetLife Investment Management LLC now owns 18,818 shares of the company’s stock worth $69,000 after purchasing an additional 5,484 shares during the last quarter. Institutional investors and hedge funds own 39.09% of the company’s stock.

Pyxis Oncology Company Profile

Pyxis Oncology, Inc, a clinical stage company, engages in the development of therapeutics to treat cancers. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors.